Company profile
Scholar Rock Holding Corp
NASDAQ:SRRKBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| APITEGROMAB | phase2 | — | 1 | no active trials |
| Linavonkibart | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07444294 | phase1 | recruiting | 2025-11-21 | 2026-12-17 | Scholar Rock, Inc. | A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults |
| NCT07047144 | phase2 | recruiting | 2025-09-15 | 2028-11-01 | Scholar Rock, Inc. | A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy |
| NCT03921528 | phase2 | completed | 2019-04-22 | 2021-01-19 | Scholar Rock, Inc. | An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy |
| NCT06445075 | phase2 | completed | 2024-05-21 | 2025-03-04 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese |
| NCT05156320 | phase3 | completed | 2022-04-14 | 2024-12-18 | Scholar Rock, Inc. | Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam |
FDA applications (0)
No records yet.